HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch

STAT+: AACR 2026: More strong data for Revolution Medicines’ KRAS drug

You're reading the web version of STAT's popup newsletter, AACR in 30 seconds, your guide to what's happening at the American Association of Cancer Researchers' annual meeting. Sign up here.We’re…

By STAT News · Apr 19, 2026 · via STAT News
STAT+: AACR 2026: More strong data for Revolution Medicines’ KRAS drug

Image: STAT News

Tags
pipelineformat:headlineheadlineSTAT News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
What actually drives speed in complex drug development programs
PipelineBioPharma Dive ↗
Learn how early coordination across functions, phases and partners can reduce risk and accelerate drug develop…
Apr 20, 2026
Small pools, big ideas: How the rare disease community is reimagining clinical trials
PipelineFierceBiotech ↗
The traditional gold standard of clinical trials with a randomized, placebo-controlled design involving hundre…
Apr 17, 2026
Qiagen launches latest diagnostic for bloodstream infections
PipelineFierceBiotech ↗
Qiagen has moved into syndromic testing for bloodstream infections with the launch of its newest offering.…
Apr 17, 2026